Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02968654
Other study ID # P2015/327
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date September 13, 2016
Est. completion date June 30, 2023

Study information

Verified date September 2023
Source Erasme University Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

To compare a "liberal" and a "restrictive" strategy to administer blood transfusions in critically ill patients with a primary brain injury.


Description:

Although blood transfusions can be lifesaving in severe hemorrhage, they can also have potential complications. As anemia has also been associated with poor outcomes in critically ill patients, determining an optimal transfusion trigger is a real challenge for clinicians. This is even more important in patients with acute brain injury who were not specifically evaluated in previous large randomized clinical trials dealing with the optimal transfusion threshold. Neurological patients may be particularly sensitive to anemic brain hypoxia because of the exhausted cerebrovascular reserve, which adjusts cerebral blood flow to tissue oxygen demand. This prospective, multicenter, randomized, pragmatic trial will compare two different strategies for red blood cell transfusion in patients with acute brain injury: a "liberal" strategy in which the aim is to maintain hemoglobin (Hb) concentrations greater than 9 g/dL and a "restrictive" approach in which the aim is to maintain Hb concentrations greater than 7 g/dL. The target population is patients suffering from traumatic brain injury (TBI), subarachnoid hemorrhage (SAH) or intracranial hemorrhage (ICH). The primary outcome is neurological outcome, evaluated using the extended Glasgow Outcome Scale (eGOS), at 180 days after the initial injury. Secondary outcomes include, amongst others, 28-day survival, intensive care unit (ICU) and hospital lengths of stay, the occurrence of extra-cerebral organ dysfunction/failure and the development of any infection or thromboembolic events (venous or arterial). The estimated sample size is 794 patients to demonstrate a reduction in the primary outcome (i.e. unfavorable neurological outcome) from 50% to 30% between groups (397 patients in each arm). The study will be initiated in September 2016 in several European ICUs and is expected at least 6 years. The results of this trial will help to improve blood product and transfusion use in this specific patient population and will provide additional data in some sub-groups of patients at high-risk of brain ischemia, such as those with intracranial hypertension or cerebral vasospasm.


Other known NCT identifiers
  • NCT02962349

Recruitment information / eligibility

Status Completed
Enrollment 850
Est. completion date June 30, 2023
Est. primary completion date December 31, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria: - Glasgow Coma Score (GCS) = 13 on randomization - Expected ICU stay > 72 hours - hemoglobin (Hb) concentration = 9 g/dL within 10 days from brain injury Exclusion Criteria: 1. Post-anoxic coma; status epilepticus without underlying brain injury; central nervous system (CNS) infections (community-acquired; hospital-acquired; ventriculitis; post-operative) 2. Known previous neurological disease, causing significant cognitive and/or motor handicap 3. ICH due to arterio-venous malformation (AVM) or brain tumor 4. Inability (religious reasons) or reduced ability (lack of compatible blood) to receive blood products 5. Active and uncontrolled bleeding at the time of enrollment 6. GCS of 3 with both pupils fixed and dilated; brain death or imminent death (within 24 hours) 7. Pregnancy 8. Medical need to correct anemia (e.g., active coronary disease or severe cardiac disease) with target Hb levels > 9 g/dL 9. do-not-escalate (DNE) orders 10. Previous allo-immunization due to transfusion, limiting red blood cells (RBC) availability

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
Restrictive Transfusion Strategy
Patients will be randomized when hemoglobin levels will be below 9 g/dl. Patients randomized to the "Restrictive Transfusion Strategy" will receive blood transfusion whenever their Hb concentration is < 7 g/dl. All patients should preferably receive one unit of blood transfusion at a time. The duration of the intervention is 28 days after randomization or until hospital discharge. Daily assessment of hemoglobin levels are mandatory only during the ICU stay. No other procedures and or interventions are scheduled. General management of patients will be conducted according to international guidelines; however, local protocols and procedures are allowed.
Liberal Transfusion Strategy
Patients will be randomized when hemoglobin levels will be below 9 g/dl. Patients randomized to the "Liberal Transfusion Strategy" will receive blood transfusion whenever their Hb concentration is < 7 g/dl. All patients should preferably receive one unit of blood transfusion at a time. The duration of the intervention is 28 days after randomization or until hospital discharge. Daily assessment of hemoglobin levels are mandatory only during the ICU stay. No other procedures and or interventions are scheduled. General management of patients will be conducted according to international guidelines; however, local protocols and procedures are allowed.

Locations

Country Name City State
Belgium Hopital Erasme Brussels

Sponsors (2)

Lead Sponsor Collaborator
Erasme University Hospital European Society of Intensive Care Medicine

Country where clinical trial is conducted

Belgium, 

Outcome

Type Measure Description Time frame Safety issue
Primary Unfavorable Neurological Outcome Unfavorable neurological outcome is defined by the extended Glasgow Outcome Scale (eGOS) of 1-5 180 days after randomization
Secondary Survival 28 days Survival 28 days
Secondary Changes in the Glasgow Coma Score (GCS) over time modification of GCS from admission over the first week and vs. the last available 28 days
Secondary ICU length of stay length of ICU stay 180 days
Secondary Hospital length of stay length oh hospital stay 180 days
Secondary Presence and severity of extra-cerebral organ dysfunction/failure Daily sequential organ failure assessment (SOFA) score 28 days
Secondary Infection rate Occurrence of any infection over the first 28 days after randomization 28 days
Secondary Composite outcome Death and Organ Failure (defined as at least one extra-cerebral organ failure, according to the specific SOFA sub-score > 2) 28 days
Secondary Brain Oxygen Pressure Absolute values of brain oxygen pressure (PbO2) for those patients where this neuromonitoring has been implemented, according to the decision of the attending physician 28 days
Secondary Daily Fluid Balance Assessment of the daily fluid balance 28 days
Secondary Serious Adverse Events (SAE) Any of the "SAE" as described in the study protocol 28 days
See also
  Status Clinical Trial Phase
Active, not recruiting NCT03651154 - Hypovolemic Phlebotomy to Reduce Blood Transfusions in Major Hepatic Resections N/A
Completed NCT01136590 - Multicenter, Randomized Placebo-controlled Clinical Trial to Evaluate the Effect of Perioperative Use of Tranexamic Acid on Transfusion Requirements and Surgical Bleeding in Major Spine Surgery Phase 4
Completed NCT00097006 - Retrovirus Epidemiology Donor Study-II (REDS-II) N/A
Completed NCT00005303 - Effectiveness of AIDS Antibody Screening N/A
Completed NCT00005319 - Epidemiologic Studies of Blood Use in the United States - SCOR in Transfusion Medicine N/A
Completed NCT00005301 - Transfusion Safety Study (TSS) N/A
Completed NCT00000581 - Granulocyte Transfusion Study Phase 3
Completed NCT04089865 - Oral Versus Intravenous Tranexamic Acid Phase 4
Enrolling by invitation NCT06019364 - Transfusion of Whole Blood in Acute Bleeding
Completed NCT04911413 - Comparison of Three Tranexamic Acid Dose Regimens in Patients Undergoing Cardiac Valve Surgery Phase 4
Completed NCT03727230 - RhD+ Blood Transfusion to Asian-type DEL Recipients N/A
Recruiting NCT06102590 - Oxygen Extraction-guided Transfusion N/A
Completed NCT00400192 - Transfusion-Associated Microchimerism in Individuals Receiving a Blood Transfusion After a Traumatic Injury N/A
Completed NCT00000593 - Viral Activation Transfusion Study (VATS) N/A
Completed NCT05581238 - Validation of a Red Blood Cell Transfusion Prediction Model in a Low Transfusion Rate Population.
Completed NCT05627544 - Blood Transfusion Applications in Hip Replacements
Not yet recruiting NCT03429790 - Cell Salvage During Caesarean Section (CSCS) N/A
Completed NCT00822588 - Comparison in Need for Bank Blood Between Patients Undergoing Total Hip Surgery That Either Receive Their Own Blood Back or Not N/A
Withdrawn NCT00269971 - A Study to Determine an Effective Dose of Epoetin Alfa to Decrease the Number of Units of Blood Required to be Transfused During Hip Replacement Surgery. Phase 3
Completed NCT03930355 - Perioperative Transfusion Related Outcome